Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding GW Pharmaceuticals plc is 'Strong Hold'. Macroaxis provides GW Pharmaceuticals buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding GWPH positions. The advice algorithm takes into account all of GW Pharmaceuticals plc available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from GWPH buy-and-hold prospective. Please also check GW Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.
For the selected time horizon GW Pharmaceuticals plc has a risk adjusted performance of (0.033672), jensen alpha of (0.25), total risk alpha of (0.53), sortino ratio of 0.0 and treynor ratio of (0.13)Macroaxis provides buy or sell advice on GW Pharmaceuticals plc to complement and cross-verify current analyst consensus on GW Pharmaceuticals. Our buy, hold, or sell suggestion engine determines the entity potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. To make sure GW Pharmaceuticals plc is not overpriced, please check out all GW Pharmaceuticals plc fundamentals including its Cash and Equivalents, Number of Employees and the relationship between Price to Sales and Book Value Per Share . Given that GW Pharmaceuticals plc has Price to Earning of (18.91)X, we strongly advise you confirm GW Pharmaceuticals market performance and probability of bankruptcy to make sure the company can sustain itself this quarter and beyond given your latest risk tolerance and investing horizon.
GW Pharmaceuticals Trading Alerts and Improvement Suggestions
GW Pharmaceuticals generates negative expected return over the last 30 days
The company reported previous year revenue of 62.82M. Net Loss for the year was (268.23M) with loss before overhead, payroll, taxes, and interest of (19.8M).
GW Pharmaceutical currently holds about 521.67M in cash with (290.82M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.98.
GW Pharmaceuticals plc exhibits very low volatility with skewness of 0.24 and kurtosis of -0.85. However, we advise investors to further study GW Pharmaceuticals plc technical indicators to make sure all market info is available and is reliable.